Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cystova-DN
- Development stage
- Unknown
- Lead developer
- MMC Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cystova-DN is an oral combination nutraceutical marketed by MMC Pharmaceuticals (formerly MMC Healthcare) under its ZIVA Ferticare division. It is primarily indicated for the management of Polycystic Ovary Syndrome (PCOS) and associated female infertility. The formulation typically contains a synergistic blend of Myo-inositol, D-chiro-inositol, Vitamin D3, and N-acetylcysteine. These components work together to address the underlying hormonal and metabolic disturbances of PCOS by improving insulin sensitivity, reducing hyperandrogenism, and promoting regular ovulation. Myo-inositol and D-chiro-inositol serve as second messengers in the insulin signaling pathway, helping to alleviate insulin resistance, while Vitamin D3 supports reproductive health and metabolic function. N-acetylcysteine provides antioxidant support as a precursor to glutathione, which helps improve oocyte quality and menstrual regularity.
- Brand names
- Cystova-DN
02
Targets
INSR (Insulin receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Cystova-DN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cystova-DN.